larazotide acetate
Start with the article narrative. Use the right sidebar to jump from prose into concept context, nearby graph relationships, and source provenance.
A peptide drug that tightens the gut's leaky junctions — targeting the entry point of gluten rather than gluten itself.
Larazotide acetate (developmental name AT-1001) is a synthetic octapeptide (8 amino acids) that works by blocking the action of zonulin, thereby tightening tight-junctions in the intestinal epithelium. Rather than degrading gliadin (like glutenases) or suppressing the immune response (like immunotherapies), larazotide acts at the physical barrier — preventing gluten peptides from crossing into the tissue where they trigger an immune cascade.
Mechanism
- gliadin normally triggers release of zonulin from enterocytes
- Zonulin loosens tight junctions → paracellular gaps open → gluten peptides cross
- Larazotide binds to the same receptor that zonulin acts on, competitively blocking zonulin's tight junction-loosening effect
- Result: tighter epithelial barrier → less gluten crosses → reduced immune activation
It can be thought of as "plugging the gate" rather than removing the trigger or suppressing the alarm.
Development History
Developed by Alba Therapeutics, later acquired by 9 Meters Biopharma.
- Phase 1/2 — positive signals: reduced symptoms in patients on an incomplete GFD; reduced intestinal permeability markers
- Phase 2b (2013) — met some endpoints; symptoms reduced; intestinal permeability improved
- Phase 3 (CeliacShield trial, ~2018–2020) — did not meet the primary endpoint (symptom reduction vs placebo over 24 weeks); development paused
- Post-hoc analyses suggested benefit in subgroups; debate continues about whether endpoints were appropriate
Why Phase 3 Failed (Hypotheses)
- The primary endpoint (GI symptom reduction) may have been too subjective and variable
- The trial may have included too many patients with good GFD adherence (reducing the treatment effect)
- Tight junction modulation may need to be combined with other approaches to show clinical benefit
- The drug may work better as protection against acute gluten exposure than as chronic disease management
Dose / Signal Pattern
A recurring theme across larazotide trials is that lower doses sometimes looked better than higher doses for symptom outcomes. That is unusual at first glance, but it fits the idea that barrier modulation may have a narrow useful range and that noisy outpatient permeability measurements make the mechanism hard to track cleanly.
Current Status
Larazotide is still not approved for celiac disease. Research interest continues — particularly for combination approaches or for a redefined patient population (e.g., NRCD patients with confirmed permeability issues). A 2024 therapy-landscape review emphasizes that larazotide may be easier to justify as an adjunct against low-level accidental exposure than as a standalone chronic disease-control drug, and a broader 2026 beyond-GFD review reinforces that its safety profile has generally looked better and more consistent than its efficacy story.
Where It Fits in the Treatment Landscape
| Treatment Type | Goal |
|---|---|
| glutenases | Destroy gluten before it crosses |
| Larazotide | Block gluten from crossing |
| IL-15 inhibitors | Suppress innate immune response after crossing |
| tolerance-induction | Teach T cells to ignore gluten |
Related Concepts
zonulin | tight-junctions | gliadin | glutenases | il-15-inhibitors | tolerance-induction | non-responsive-celiac
Source Basis
This page draws on:
raw/biomedicines-14-00029-v2.pdf(Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet, 2026), especially for the recurring low-dose signal pattern, mixed barrier-readout results, and later-stage status framingraw/cogas-41-124.pdf(New therapies in celiac disease, 2025), which refreshes the larazotide mechanism, symptom-signal, and phase-3-readiness framing inside the broader non-dietary therapy landscape